4-(2-chlorophenylsulfonyl)-6,6a,7,8,9,10-hexahydro-4H-pyrazino[1,2-a]pyrrolo[4,3,2-de]quinoline | 1315563-17-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 4-(2-chlorophenylsulfonyl)-6,6a,7,8,9,10-hexahydro-4H-pyrazino[1,2-a]pyrrolo[4,3,2-de]quinoline
• 英文别名: 11-(2-Chlorophenyl)sulfonyl-2,5,11-triazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(15),9,12(16),13-tetraene
• CAS: 1315563-17-7
• 化学式: C₁₉H₁₈ClN₃O₂S
• 分子量: 387.89
• InChiKey: PJALJOKVVODHLM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  26
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  62.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4-(1H-4-吲哚)-哌嗪-1-羧酸叔丁酯 在 盐酸 、 苄基三乙基氯化铵 、 四丁基硫酸氢铵 、 magnesium 、 对甲苯磺酰肼 、 sodium hydroxide 、 三氯氧磷 作用下， 以 四氢呋喃 、 甲醇 、 乙醚 、 水 、 甲苯 为溶剂， 反应 9.95h， 生成 4-(2-chlorophenylsulfonyl)-6,6a,7,8,9,10-hexahydro-4H-pyrazino[1,2-a]pyrrolo[4,3,2-de]quinoline
  参考文献：
  名称：

  Novel Aza-analogous Ergoline Derived Scaffolds as Potent Serotonin 5-HT₆ and Dopamine D₂ Receptor Ligands.

  摘要：

  By introducing distal substituents on a tetracyclic scaffold resembling the ergoline structure, two series of analogues were achieved exhibiting subnanomolar receptor binding affinities for the dopamine D-2 and serotonin S-HT6 receptor subtype, respectively. While the S-HT6 ligands were antagonists, the D-2 ligands displayed intrinsic activities ranging from full agonism to partial agonism with low intrinsic activity. These structures could potentially be interesting for treatment of neurological diseases such as schizophrenia, Parkinson's disease, and cognitive deficits.

  DOI：

  10.1021/jm5003759

文献信息

• [EN] NOVEL 4-(ARYL-4-SULFONYL)-6,6a,7,8,9,10-HEXAHYDRO-4H-4,8,10a-TRIAZA-ACEPHENANTHRYLENE AND 3-ARYLSULFONYL-6,6a,7,8,9,10-HEXAHYDRO-3H-3,8,10a-TRIAZA-CYCLOPENTA[C]FLUORENE DERIVATIVES AS SEROTONIN 5-HT6 LIGANDS<br/>[FR] NOUVEAUX DÉRIVÉS DE 4-(ARYL-4-SULFONYL)-6,6A,7,8,9,10-HEXAHYDRO-4H-4,8,10A-TRIAZA-ACÉPHÉNANTHRYLÈNE ET 3-ARYLSULFONYL-6,6A,7,8,9,10-HEXAHYDRO-3H-3,8,10A-TRIAZA-CYCLOPENTA[C]FLUORÈNE EN TANT QUE LIGANDS DE SÉROTONINE 5-HT6
  申请人：LUNDBECK & CO AS H

  公开号：WO2011088836A1

  公开（公告）日：2011-07-28

  This invention is directed to compounds of formula I or II, which are serotonin 5-HT 6 ligands. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula I or II, or a pharmaceutically acceptable salt thereof. The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I or II, or a pharmaceutically acceptable salt thereof. The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I or II, or a pharmaceutically acceptable salt thereof.

  本发明涉及式I或II的化合物，它们是血清素5-HT6受体配体。本发明提供了一种药物组合物，其包含本发明的化合物以及药学上可接受的载体的治疗有效量。本发明还提供了制备式I或II的化合物或其药学上可接受的盐的方法。本发明进一步提供了一种治疗患有神经退行性疾病的受试者的方法，包括向该受试者施用式I或II的化合物或其药学上可接受的盐的治疗有效量。本发明还提供了一种治疗患有精神疾病的受试者的方法，包括向该受试者施用式I或II的化合物或其药学上可接受的盐的治疗有效量。
• Novel Aza-analogous Ergoline Derived Scaffolds as Potent Serotonin 5-HT₆ and Dopamine D₂ Receptor Ligands.
  作者：Niels Krogsgaard-Larsen、Anders A. Jensen、Tenna J. Schrøder、Claus. T. Christoffersen、Jan Kehler

  DOI：10.1021/jm5003759

  日期：2014.7.10

  By introducing distal substituents on a tetracyclic scaffold resembling the ergoline structure, two series of analogues were achieved exhibiting subnanomolar receptor binding affinities for the dopamine D-2 and serotonin S-HT6 receptor subtype, respectively. While the S-HT6 ligands were antagonists, the D-2 ligands displayed intrinsic activities ranging from full agonism to partial agonism with low intrinsic activity. These structures could potentially be interesting for treatment of neurological diseases such as schizophrenia, Parkinson's disease, and cognitive deficits.